Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7988545 | 0.81 | SLC1A3 (0.41) | SLC1A3MAPTGAAKDM4EGLA | |
| SCHEMBL7062605 | 0.80 | PLAU (0.43) | MAPTGAAKDM4EGLATDP1 | |
| SCHEMBL548327 | 0.80 | NQO2 (0.49) | TDP1ALDH1A1HPGDPRSS1TMPRSS15 | |
| SCHEMBL6655085 | 0.78 | PLAU (0.49) | TDP1LMNASLC6A2SLC6A3SMN1; SMN2 | |
| SCHEMBL7307963 | 0.77 | KMT2A (0.50) | MAPTKDM4ETDP1LMNACYP3A4 | |
| Hydrochloric Acid SCHEMBL15251731 | 0.77 | PLAU (0.48) | TDP1LMNASLC6A2SLC6A3SMN1; SMN2 | |
| SCHEMBL13882702 | 0.76 | SLC1A3 (0.47) | SLC1A3MAPTGAAKDM4ETHRB | |
| SCHEMBL3862551 | 0.76 | MASP2 (0.46) | MAPTKDM4ETDP1LMNACYP3A4 | |
| SCHEMBL2551644 | 0.75 | ALDH1A1 (0.55) | SLC1A3MAPTGAAKDM4ETHRB | |
| SCHEMBL8301048 | 0.75 | MAOA (0.45) | MAPTGAATDP1CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3532057-B1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3532057-B1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-01 | — | — | US | disclosed |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2018081513-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | KLKB1, SERPINB1, KLK1 | SLC1A3 2036/4885MAPT 3099/4885GAA 366/4885 |
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | SLC1A3 2036/4885MAPT 3099/4885GAA 366/4885 |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | SLC1A3 2036/4885MAPT 3099/4885GAA 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.